News

The biosimilar market experienced 16 new approvals by early December 2025, marking significant expansion and introducing previously unavailable biosimilar drug classes to patients.

An analysis of patients with stage III colon patients found celecoxib improves survival only in those who are positive for circulating tumor DNA.

Teledermatology revolutionized skin care in 2025, enhanced access and efficiency through virtual tools and AI while addressing safety and trust concerns.

A study of more than 1 million UK medical records found that getting a flu vaccine between ages 40 and 50 did not increase Parkinson’s disease risk and was even associated with a lower estimated prevalence eight years later, suggesting a possible protective effect that warrants further research.

Medicare's first negotiated drug prices, effective January 2026, provide modest discounts, with limited savings for most beneficiaries and some unintended consequences.

A new Tufts study found that Medicare price negotiations on biologics with imminent biosimilars could lead to near-term savings, but greater savings are likely from biosimilar competition.

High consumption of ultra-processed foods elevates the risk of early-onset colorectal cancer, highlighting the need for improved dietary quality for prevention.

Results from a recent ianalumab treatment trial signal a potential for longer-lasting disease control for patients with primary immune thrombocytopenia.

Sanofi introduces Qfitlia earlier this year, a groundbreaking hemophilia treatment, offering flexible dosing and support for patients transitioning from existing therapies.

Jeff Schaffnit discusses Sanofi's advancements in BTK inhibitors and promising results for hemophilia A therapies at ASH 2025, enhancing treatment options.

Melanoma survival rates have doubled since 2009. New treatments, including oncolytic viruses, fecal transplants, and engineered antibodies, have shown promising results in clinical trials.

Clinicians are moving toward managing mild (Grade 1) cytokine release syndrome on an outpatient basis.

The CAR T Vision Steering Committee members wish to double the number of eligible patients receiving chimeric antigen receptor (CAR) T-cell therapy by 2030 through disease awareness and sustainable financing options, according to George Eastwood, Executive Director of the Emily Whitehead Foundation and recent CAR T Vision Steering Committee member.

New drug approvals in dermatology in 2025 included a gene therapy for rare skin disorders and targeted treatments for two conditions.

Flipped dosing of Yervoy and Opdivo produced a 49% response rate compared with 37% for the standard dose of the combination and extended survival to 42 months from 14 months in a Swedish study.

As the number of patients with multiple myeloma and lymphoma treated with CAR-T therapy increases, health systems are shifting post-infusion care from inpatient to outpatient settings. Research presented at the annual meeting of the American Society of Hematology shows the change slices costs by $19,180.

Tranexamic acid given during noncardiac surgery reduced blood transfusions by 2.4% without increasing blood clots, potentially saving millions of transfusion units annually nationwide.

A phase 3 trial showed that Jaypirca improved progression-free survival in newly diagnosed patients with chronic lymphocytic leukemia and small lymphocytic lymphoma compared with standard chemotherapy/rituximab regimen.

Dermatologists explore chronic itch advancements, revealing new treatments and insights into its complex biology, lifestyle impacts and future care strategies.

Chimeric antigen receptor (CAR) T-cell therapy can cure certain types of blood cancer, but cost and a general lack of awareness around the therapy are barriers to care, according to George Eastwood, Executive Director of the Emily Whitehead Foundation.

In this interview, George Eastwood, Executive Director of the Emily Whitehead Foundation and CAR T Vision steering committee member discusses barriers and strategies for expanding access to CAR T-cell therapy.

Early results from the LINKER-MM4 trial show high response rates for linvoseltamab, offering new hope for newly diagnosed patients.

Early results from the LINKER-MM4 trial reveal promising response rates for linvoseltamab in newly diagnosed multiple myeloma patients, with manageable side effects.

Jaypirca demonstrated non-inferior response rates compared with Imbruvica in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma, with fewer cardiovascular events and dose reductions.

Here’s what you missed this week on Managed Healthcare Executive.

Venclexta-azacitidine combination offered better responses with less hospitalization and lower symptom burden compared with standard chemotherapy in patients with acute myeloid leukemia who are fit for transplant.

The chief medical officer of Genetix Biotherapeutics, formerly known as Bluebird bio, discusses timelines and operational challenges of the gene therapies Zynteglo for beta thalassemia and Lyfgenia for sickle cell disease.